Processing PDF: /home/ngobiro/projects/pngobiro.github.io/colleges/kmtc/diploma/Diploma in Kenya Registered Community Health Nursing/Year 1/Cardiovascular Nursing/CARDIOLOGY SERIES LECTURES/pdfs/9. CARDIOMYOPATHIES.pdf
Starting PDF processing...
PDF processing started. ID: 2025_06_29_291ab3b328d2bf2fdde5g
Polling PDF status (ID: 2025_06_29_291ab3b328d2bf2fdde5g)...
Attempt 1: Status = completed, Progress = 100.0%
PDF processing completed successfully.
Fetching MMD result (ID: 2025_06_29_291ab3b328d2bf2fdde5g)...

--- Converted MMD Start ---
\title{
CARDIOMYOPATHY
}

\author{
By:
}

\author{
Dr. Murithi Nyamu Physician/ Cardiologist
}

\section*{Cardiomyopathies}
- Definition: diseases of heart muscle
- 1980 WHO: unknown causes
- Not clinically relevant

■ 1995 WHO: "diseases of the myocardium associated with cardiac dysfunction "
- pathophysiology
- each with multiple etiologies

\section*{Cardiomyopathy}

\section*{WHO Classification}
anatomy \& physiology of the LV
1. Dilated
- Enlarged
- Systolic dysfunction
2. Hypertrophic
- Thickened
- Diastolic dysfunction
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-03.jpg?height=623&width=1066&top_left_y=470&top_left_x=1431)
3. Restrictive
- Diastolic dysfunction
4. Arrhythmogenic RV dysplasia
- Fibrofatty replacement
5. Unclassified
- Fibroelastosis
- LV noncompaction
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-03.jpg?height=604&width=1069&top_left_y=1101&top_left_x=1430)

Circ 93:841, 1996

\section*{CM: Specific Etiologies}

Ischemic
- Valvular

■ Hypertensive
- Inflammatory
- Metabolic
- Inherited
- Toxic reactions
- Peripartum

Ischemic: thinned, scarred tissue
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-04.jpg?height=1127&width=1203&top_left_y=629&top_left_x=1235)

\section*{Dilated Cardiomyopathy}
-Dilation and impaired contraction of ventricles:
-Reduced systolic function with or without heart failure
-Characterized by myocyte damage
-Multiple etiologies with similar resultant pathophysiology
-Majority of cases are idiopathic
-incidence of idiopathic dilated CM 5-8/100,000
-incidence likely higher due to mild, asymptomatic cases
-3X more prevalent among males and African-Americans

\section*{DCM: Etiology}

Ischemic
Valvular
Hypertensive
Familial
Idiopathic
Inflammatory
Infectious
Viral - picornovirus, Cox B, CMV, HIV
Ricketsial - Lyme Disease
Parasitic - Chagas' Disease, Toxoplasmosis
Non-infectious
Collagen Vascular Disease (SLE, RA)
Peripartum
Toxic
Alcohol, Anthracyclins (adriamycin), Cocaine
Metabolic
Endocrine -thyroid dz, pheochromocytoma, DM, acromegaly,
Nutritional
Thiamine, selenium, carnitine
Neuromuscular (Duchene's Muscular Dystrophy--x-linked)

\section*{DCM: Infectious}

Acute viral myocarditis
- Coxasackie B or echovirus
- Self-limited infection in young people
- Mechanism?:
- Myocyte cell death and fibrosis
- Immune mediated injury
- BUT:

■ No change with immunosuppressive drugs

\section*{DCM: toxic}

Alcoholic cardiomyopathy
- Chronic use
- Reversible with abstinence
- Mechanism?:
- Myocyte cell death and fibrosis
- Directly inhibits:
- mitochondrial oxidative phosphorylation
- Fatty acid oxidation

\section*{DCM: inherited}

Familial cardiomyopathy
- 30\% of 'idiopathic'
- Inheritance patterns
- Autosommal dom/rec, x-linked, mitochondrial
- Associated phenotypes:
- Skeletal muscle abn, neurologic, auditory
- Mechanism:
- Abnormalities in:
- Energy production
- Contractile force generation
- Specific genes coding for:

■ Myosin, actin, dystophin...

\section*{DCM: Peripartum}

Diagnostic Criteria
- 1 mo pre, 5 mos post

■ Echo: LV dysfunction
- LVEF < 45\%
- LVEDD > $2.7 \mathrm{~cm} / \mathrm{m} 2$
- Epidemiology/Etiology
- 1:4000 women
- JAMA 2000;283:1183
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-10.jpg?height=751&width=948&top_left_y=645&top_left_x=1497)
- Proposed mechanisms:
- Inflammatory Cytokines:
- TNFa, IL6, Fas/AP01
- JACC 2000 35(3):701.

\section*{MECHANISMS IN HEART FATLURE}

Ischemic injury
Myocardial disease
Genetics

Neurohormones
Cytokines
Oxidative stress
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-11.jpg?height=1235&width=498&top_left_y=492&top_left_x=204)

Altered molecular expression Ultrastructural changes
Myocyte hypertrophy
Myocyte contractile dysfunction
Apoptosis
Fibroblast proliferation
Collagen deposition
Ventricular remodeling
Hemodynamic Derangement
Clinical Heart Failure
Arrhythmia
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-11.jpg?height=1168&width=514&top_left_y=500&top_left_x=1854)

\section*{Pathophysiology}
-Initial Compensation for impaired myocyte contractility:
-Frank-Starling mechanism
-Neurohumoral activation
- $\uparrow$ intravascular volume
-Eventual decompensation
-ventricular remodeling
-myocyte death/apoptosis
-valvular regurgitation

\section*{Pathophysiology: Neurohumoral}
- Adrenergic nervous system
- Renin-angiotensinaldosterone axis
- Vasopressin
- Natriuretic peptides

■ Endothelin

MEDIAN PLASMA NOREPINEPHRINE LEVELS
(pg/mL)
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-13.jpg?height=706&width=1034&top_left_y=757&top_left_x=1275)

From: Francis. Circulation. 1990;82:1724-1729.

\section*{Renin-Angiotensin-Aldosterone Pathways}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-14.jpg?height=1381&width=2415&top_left_y=400&top_left_x=81)

\section*{Angiotensin-II Effects}
- Vasoconstriction
- Aldosterone production
- Myocyte hypertrophy
- Fibroblast proliferation
- Collagen deposition
- Apoptosis
- Pro-thrombotic
- Pro-oxidant
- Adrenergic stimulation
- Endothelial dysfunction

\section*{The Kidney in Heart Failure}
- Reduced renal blood flow
- Reduced glomerular filtration rate
- Increased renin production
- Increased tubular sodium reabsorption
- Increased free water retention (vasopressin)

\section*{Clinical Findings}

\section*{Biventricular Congestive Heart Failure}
-Low forward Cardiac Output
-fatigue, lightheadedness, hypotension
-Pulmonary Congestion
-Dyspnea,
-orthopnea, \& PND
-Systemic Congestion
-Edema
-Ascites
-Weight gain
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-17.jpg?height=1050&width=1120&top_left_y=744&top_left_x=1302)

\section*{Physical Exam}
```
Decreased C.O.
    Tachycardia
    \downarrow \mathrm { BP } \text { and pulse pressure }
    cool extremities (vasoconstriction)
    Pulsus Alternans (end-stage)
Pulmonary venous congestion:
    rales
    pleural effusions
Cardiac:
    laterally displaced PMI
    S3 (acutely)
    mitral regurgitation murmur
Systemic congestion
    \uparrow JVD
    hepatosplenomegaly
    ascites
    peripheral edema
```


\section*{Diagnostic Studies}

CXR -enlarged cardiac silhouette, vascular redistribution interstitial edema, pleural effusions
EKG -normal
tachycardia, atrial and ventricular enlargement, LBBB, RBBB, Q-waves
Blood Tests
(ANA,RF, Fe ${ }^{2+}$, TFT's,ferritin,)
Echocardiography
LV size, wall thickness function valve dz, pressures
Cardiac Catheterization
hemodynamics
LVEF
angiography
Endomyocardial Biopsy

\section*{Criteria for NYHA Functional Classification}

Class 1: No limitation of physical activity.
Ordinary physical activity w/o fatigue, palpitation, or dyspnea.

Class 2: Slight limitation of physical activity. Comfortable at rest, but symptoms w/ ordinary physical activity

Class 3: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.

Class 4: Unable to carry out any physical activity without discomfort. Symptoms include cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.

\section*{Aim of Treatment}
- Preload reduction
- Diuretics
- venodilators
- Vasodilators
- ACEI
- Inotropes
- Acutely
- Chronically
- mortality
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-21.jpg?height=1040&width=1107&top_left_y=561&top_left_x=1226)

\section*{Vasodilator Agents in Heart Failure}
\begin{tabular}{|l|l|l|l|}
\hline Drug & Mechanism & Action & Use \\
\hline Nitroglycerin and longacting nitrates* & Direct via nitric oxide & Veno / arterioloar & Hemodynamic; anti-ischemic; long term \\
\hline Nitroprusside & Direct via nitric oxide & Arteriolar > venodilation & Hemodynamic \\
\hline Hydralazine* & Direct & Arteriolar & ?long term* \\
\hline ACE inhibitors\# & Reduced A-II Incr. bradykinin & Veno / arterioloar & Long-term \\
\hline
\end{tabular}
*Hydralazine and a long-nitrate shown to reduce mortality long-term \# Other actions (aside from vasodilation) likely to be important

\section*{CRT: Cardiac Resynchronization Therapy}
1. Improved hemodynamics
- Increased CO
- Reduced LV filling pressures
- Reduced sympathetic activity
- Increased systolic function w/o MVO2
2. Reverse LV remodeling/architecture
- Decreased LVES/ED volumes
- Increased LVEF
- Circ '02, JACC '02, JACC '02, NEJM'02
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-23.jpg?height=967&width=957&top_left_y=575&top_left_x=1301)

\section*{Anti-arrhythmic drugs, ICD placebo and Death}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-24.jpg?height=1251&width=2063&top_left_y=427&top_left_x=225)

\section*{Diastolic Dysfunction}

40-50\% of pts w/ CHF have nml LVEF
- Vasan JACC '99
- Grossman Circ '00
- Prevalence:
- increases with age
- higher in women

■ Etiology: HTN \& LVH
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-25.jpg?height=725&width=1037&top_left_y=741&top_left_x=1331)
- Diagnosis:
- MV\& PV Doppler
- TDI, Color m-mode

\section*{Hypertrophic Cardiomyopathy}

Left ventricular hypertrophy not due to pressure overload Hypertrpohy is variable in both severity and location:
-asymmetric septal hypertrophy
-symmetric (non-obstructive)
-apical hypertrophy

Vigorous systolic function, but impaired diastolic function impaired relaxation of ventricles elevated diastolic pressures
prevalence as high as 1/500 in general population mortality in selected populations 4-6\% (institutional) probably more favorable ( $\leq 1 \%$ )

\section*{Etiology}

Familial in ~ 55\% of cases with autosomal dominant transmission Mutations in one of 4 genes encoding proteins of cardiac sarcomere account for majority of familial cases
$\beta$-MHC
cardiac troponin T myosin binding protein C $\alpha$-tropomyosin

Remainder are spontaneous mutations.
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-27.jpg?height=888&width=1599&top_left_y=704&top_left_x=846)

\section*{Hypertrophic Cardiomyopathy}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-28.jpg?height=1496&width=2064&top_left_y=317&top_left_x=275)

\section*{Hypertrophic Cardiomyopathy}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-29.jpg?height=1526&width=2207&top_left_y=283&top_left_x=156)

\section*{Lossy compression - not intended for diagnosis}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-30.jpg?height=1636&width=2390&top_left_y=196&top_left_x=55)
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-31.jpg?height=1636&width=2138&top_left_y=196&top_left_x=95)

\section*{Pathophysiology}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-32.jpg?height=1238&width=1975&top_left_y=440&top_left_x=282)

\section*{HCM with outflow obstruction}

Dynamic LVOT obstruction (may not be present at rest)
SAM(systolic anterior motion of mitral valve)
LVOT Obstruction $\Rightarrow$ LVOT gradient
$\Rightarrow$ 个wall stress $\Rightarrow$ 个MVO2 $\Rightarrow$ ischemia/angina
$\uparrow$ LVOT gradient: $\uparrow$ HR (DFP), $\downarrow$ preload (LVEDV), $\downarrow$ afterload(BP).
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-33.jpg?height=686&width=878&top_left_y=365&top_left_x=1621)
$\downarrow$ LVOT gradient: $\uparrow$ BP (Afterload), $\uparrow$ LVEDV(preload)

Symptoms of dyspnea and angina more related to diastolic dysfunction than to outflow tract obstruction
Syncope: LVOT obstruction (failure to increase CO during exercise or after vasodilatory stress) or arrhythmia.

\section*{Physical Exam}

Bisferiens pulse ("spike and dome")
S4 gallop
Crescendo/Descrescendo systolic ejection murmur

HOCM vs. Valvular AS

Valsalva ( $\downarrow$ preload, $\downarrow$ afterload)
Squatting ( $\uparrow$ preload, $\uparrow$ afterload)
Standing ( $\downarrow$ preload, $\downarrow$ afterload)

Intensity of murmur
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-34.jpg?height=390&width=651&top_left_y=956&top_left_x=1556)

Holosystolic apical blowing murmur of mitral regurgitation

\section*{Diagnostic Studies}
- EKG
- NSR
- LVH
- septal Q waves
- 2D-Echocardiography
- LVH; septum >1.4x free wall
- LVOT gradient by Doppler
- Systolic anterior motion of the mitral valeregurgitation
- Cardiac Catheterization
- LVOT gradient and pullback
- provocative maneuvers
- Brockenbrough phen
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-35.jpg?height=731&width=1033&top_left_y=738&top_left_x=1330)

HCM-ASH using contrast

\section*{Cardiac Catheterization}

LV pullback
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-36.jpg?height=508&width=1381&top_left_y=221&top_left_x=566)

Brockenbrough-Braunwald Sign
failure of aortic pulse pressure to rise post PVC
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-36.jpg?height=715&width=1106&top_left_y=1106&top_left_x=107)

Provocative maneuvers:
Valsalva amyl nitrate inhalation
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-36.jpg?height=772&width=1082&top_left_y=1052&top_left_x=1366)

\section*{Atrial Fibrillation}

Acute A. Fib is poorly tolerated -Acute Pulmonary Edema and Shock Chronic a fib - Fatigue, dyspnea and angina

Rapid HR - decreased time for diastolic filling and LV relaxation Loss of atrial "Kick" - decreased LV filling
- decreased SV and increased outflow tract obstruction
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-37.jpg?height=664&width=1541&top_left_y=784&top_left_x=489)

Rate slowing with $\beta$-blockers and $\mathrm{Ca} 2+$ channel blockers Digitalis is relatively contra-indicated- positive inotrope DC Cardioversion

\section*{Treatment}

For symptomatic benefit
$\beta$-plockers
$\downarrow \mathrm{mvO} 2$
$\downarrow$ gradient (exercise) arrythmias
Calcium Channel blockers
Anti-arrhythmics afib
amiodorone Disopyramide AICD for sudden death
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-38.jpg?height=1098&width=951&top_left_y=325&top_left_x=1511)
antibiotic prophylaxis for endocarditis
No therapy has been shown to improve mortality

\section*{HCM: Surgical Treatment}

For severe symptoms with large outflow gradient ( $>50 \mathrm{mmHg}$ ) Does not prevent Sudden Cardiac Death

Myomyectomy
removal of small portion of upper IV septum
+/- mitral valve replacement
5 year symptomatic benefit in ~ 70\% of patients

Dual Camber (DDD pacemaker) pacing
decreases LVOT gradient (by~25\%)
randomized trials have shown little longterm benefit possible favorable morphologic changes

ETOH septal ablation
AICD to prevent sudden death

\section*{Hypertrophic CM}
-Most common cause of death in young people.
- The magnitude of left ventricular hypertrophy is directly correlated to the risk of SCD.
- Young pts with extreme hypertrophy and few or no symptoms are at substantial long-term risk of SCD.

\section*{Prognosis}

Sudden Death
2-4\%/year in adults
4-6\% in children/adolescents
AICD for:
survivors of SCD with Vfib
episodes of Sustained VT
pts with family hx of SCD in young family members
High risk mutation (TnT, Arg403Gln)
Predictors of adverse prognosis:
early age of diagnosis
familial form with SCD in 1st degree relative
history of syncope
ischemia
presence of ventricular arrhythmias on Holter (EPS)
EPS
Amiodorone (low dose)
Prophylactic AICD?

\section*{Restrictive Cardiomyopathy}

\section*{Characterized by:}
- impaired ventricular filling due to an abnormally stiff (rigid) ventricle
-normal systolic function (early on in disease)
-intraventricular pressure rises precipitously with small increases in volume
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-42.jpg?height=479&width=1082&top_left_y=1055&top_left_x=333)

Causes : infiltration of myocardium by abnormal substance fibrosis or scarring of endocardium

Table 4. Causes of Restrictive Cardiomyopathy.
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-43.jpg?height=1347&width=903&top_left_y=286&top_left_x=301)

Amyloid infiltrative CM

\section*{Myocardial}

Noninfiltrative disorders
Idiopathic disease
Familial disease
Hypertrophy
Scleroderma
Diabetes mellitus
Pseudoxanthoma elasticum
Infiltrative disorders
Amyloidosis
Sarcoidosis
Gaucher's disease
Hurler's syndrome
Fatty infiltration
Storage disorders
Hemochromatosis
Fabry's disease
Glycogen storage disease

\section*{Endomyocardial}

Endomyocardial fibrosis
Hypereosinophilic (Löffler's) syndrome
Carcinoid syndrome
Metastatic cancer
Exposure to radiation
Toxins
Anthracycline (doxorubicin or daunorubicin)
Serotonin
Methysergide
Ergotamine
Mercurial agents
Busulfan

\section*{Amyloidosis}

Primary Amyloidosis
immunoglobulin light chains -- multiple myeloma
Secondary Amyloidosis
deposition of protein other than immunoglobulin senile
familial chronic inflammatory process
restriction caused by replacement of normal myocardial contractile elements by infiltrative interstitial deposits

\section*{Amyloidosis}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-45.jpg?height=1442&width=2407&top_left_y=325&top_left_x=49)

\section*{Amyloid Cardiomyopathy}

\section*{Sarcoidosis}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-47.jpg?height=1142&width=1184&top_left_y=357&top_left_x=94)

\author{
Restriction \\ Conduction System Disease \\ Ventricular Arrhythmias \\ (Sudden Cardiac Death)
}

\section*{Endomyocardial Fibrosis}

Endemic in parts of Africa, India, South and Central America, Asia 15-25\% of cardiac deaths in equatorial Africa hypereosinophilic syndrome (Loffler's endocarditis)
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-48.jpg?height=757&width=996&top_left_y=655&top_left_x=197)

Thickening of basal inferior wall endocardial deposition of thrombus apical obliteration mitral regurgitation 80-90\% die within 1-2 years
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-48.jpg?height=1015&width=811&top_left_y=637&top_left_x=1514)

\section*{Pathophysiology of Restriction}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-49.jpg?height=585&width=952&top_left_y=326&top_left_x=369)
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-49.jpg?height=512&width=1685&top_left_y=908&top_left_x=366)

Elevated systemic and pulmonary venous pressures right and left sided congestion reduced ventricular cavity size with $\downarrow$ SV and $\downarrow$ CO

\section*{Clinical Findings}

Right > Left heart failure
Dyspnea
Orthopnea/PND
Peripheral edema
Ascites/Hepatomegaly
Fatigue/ $\downarrow$ exercise tolerance

\section*{Clinically mimics constrictive Pericarditis}

\section*{Diagnostic Studies}

2D-Echo/Dopplermitral in-flow velocity rapid early diastolic filling

Catheterization -
diastolic pressure equilibration restrictive vs constrictive hemodynamics

Endomyocardial biopsydefinite Dx of restrictive pathology
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-51.jpg?height=1503&width=945&top_left_y=304&top_left_x=1466)

\section*{Cardiac Catheterization}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-52.jpg?height=1140&width=859&top_left_y=323&top_left_x=154)
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-52.jpg?height=923&width=1296&top_left_y=425&top_left_x=1112)

Prominent y descent rapid atrial emptying
"dip and plateau" rapid ventricular filling then abrupt cessation of blood flow due to non-compliant myocardium

\section*{Constriction vs. Restrictive CM}

Table 2. The Differential Diagnosis of Restrictive Cardiomyopathy and Constrictive Pericarditis.*

\section*{Type of Evaluation}

Physical examination

Electrocardiography

Echo cardiography

Doppler studies

Cardiac catheterization

Endomyo cardial biopsy
CT/MRI

\section*{Restrictive Cardionyopathy}

Kussmaul's sign may be present
Apical impulse may be prominent
S3 may be present, rarely S4
Regurgtant murmurs $\infty$ mmon
Low voltage (especially in amyloidosis), pseudoinfarction, left-axis deviation, atrial fibrillation, conduction disturbances common
Increased wall thickness (especially thickened interatrial septum in amyloidosis)
Thickened cardiac valves (amyloidosis)
Granular sparkling texture (amyloid)
Decreased RV and LV velocities with inspiration
Inspiratory augmentation of hepatic-vein diastolic flow reversal
Mitral and tricuspid regurgitation common
LVEDP often $>5 \mathrm{~mm} \mathrm{Hg}_{\text {greater than RVEDP }}$, but may be identical

May reveal specific cause of restrictive cardiomyopathy
Pericardium usually normal

\section*{Constrictive Pericarditis}

Kussmaul's sign usually present
Apical impulse usually not palpable
Pericardial lcnock may be present
Regurgitant murmurs uncommon
Low voltage ( $<50$ percent)

Normal wall thickness
Pericardial thickening may be seen
Prominent early diastolic filling with abrupt displacement of interventricular septum
Increased RV systolic velocity and decreased LV systolic velocity with inspiration
Expiratory augmentation of hepatic-vein diastolic flow reversal
RVEDP and LVEDP usually equal
RV systolic pressure $<50 \mathrm{~mm} \mathrm{Hg}$
RVEDP >one third of RV systolic pressure
May be normal or show nonspecific myocyte hypertrophy or myocardial fibrosis
Pericardium may be thickened

\footnotetext{
*LV denotes left ventricular, RV right ventricular, LVEDP left ventricular end-diastolic pressure, RVEDP right ventricular end-diastolic pressure, CT computed tomography, and MRI magnetic resonance imaging.
}

\section*{Treatment}

Treat underlying cause
r/o constriction which is treatable (restriction poor prognosis)
amyloid (melphalan/prednisone/colchicine)
Endomyocardial Fibrosis (steroids, cytotoxic drugs, MVR)
Hemochromatosis (chelation, phlebotomy)
Sarcoidosis (steroids)
Diuretics
For congestive symptoms, but $\downarrow$ LV/RV filling $\Rightarrow \downarrow$ CO
Digoxin (avoid in amyloidosis)
Antiarrhythmics for afib amiodorone
Pacemaker for conduction system disease
Anticoagulation for thrombus (esp in atrial appendages)

\section*{Arrhythmogenic RV Dysplasia}
- Myocardium of RV free wall replaced:
- Fibrofatty tissue
- Regional wall motion/function is reduced
- Ventricular arrhythmias
- SCD in young

\section*{MRI: RV Dysplasia}

\section*{LV Noncompaction}

\section*{Diagnostic Criteria}
- Prominent trabeculations, deep recesses in LV apex
- Thin compact epicardium, thickened endocardium
- Stollberger C, JASE `04
- Other phenotypic findings

\section*{Prognosis and Treatment}
- Increased risk of CHF, VT/SCD, thrombosis
- Oechslin EN, JACC '00
- Hereditary risk
- Screening of offspring
- Pregnancy: case report

\section*{Echo: LV Noncompaction}
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-58.jpg?height=741&width=2028&top_left_y=742&top_left_x=280)

\section*{Cardiomyopathy}

\section*{WHO Classification}
anatomy \& physiology of the LV
1. Dilated
- Enlarged
- Systolic dysfunction
2. Hypertrophic
- Thickened
- Diastolic dysfunction
3. Restrictive
- Myocardial stiffness
- Diastolic dysfunction
4. Arrhythmogenic RV dysplasia
- Fibrofatty replacement
5. Unclassified
- Fibroelastosis
- LV noncompaction
![](https://cdn.mathpix.com/cropped/2025_06_29_291ab3b328d2bf2fdde5g-59.jpg?height=1229&width=1069&top_left_y=471&top_left_x=1430)
--- Converted MMD End ---
